Skip to main content
European Commission logo
Live, work, travel in the EU
COVID-19 In Vitro Diagnostic Devices and Test Methods Database

Scientific literature on COVID-19 Test Methods and Devices - detail

Evaluation of commercially available immuno-magnetic agglutination and enzyme-linked immunosorbent assays for rapid point-of-care diagnostics of COVID-19

DOI
10.1101/2020.08.15.20172080 
Detection Principle
ImmunoAssay-Antibody
Target
IgM/IgA or IgG (IMA); IgA/IgG (ELISA)
Testing Method Category
 
Testing Method
microfluidic quantitative immunomagnetic assay (IMA) and ELISA kit
Testing Method - Additional Info
microfluidic quantitative immunomagnetic assay (IMA)(ViroTrack Sero COVID IgM+IgA/IgG Ab, Blusense Diagnostics, Denmark) ; enzyme-linked immunosorbent assay ((ELISA) (EuroImmun Medizinische Labordiagnostika, Germany).
Reported Performance
Sensitivity: 68% (IgA+IgM by IMA), 73% (IgG by IMA), 73% (IgG by ELISA), 90% (Ima and Elisa, >14 dpo); Specificity: 100% (IMA), 95% (ELISA IgA), 97.5% (ELISA IgG)
Sample Size
35 plasma from 22 patients & 40 controls
Peer-reviewed
no

The database contains available information from scientific literature that is being updated periodically. Please note that the provided information (as retrieved from analysed papers) is provided only for devices commercially available with CE-IVD mark. Acknowledgements